Sinfonia Biotherapeutics’ NeuRepair product SB0101 demonstrates excellent product characteristics

Oct 20, 2022

Sinfonia’s lead compound SB0101 for treatment of chronic sciatica is an injectable biologic that has demonstrated impressive pain lowering activities in clinical studies. In preparation for further clinical development, new stability data of the protein drug have been generated. “We have been able to demonstrate that SB0101 is an extraordinary stable biologic with a refrigerated (+4-8 °C) shelf life for more than 14 years and at room temperature for 8 years”. These are excellent qualities for a biologic and encouraging news since it will simplify future manufacturing, global distribution, and use of SB0101 in primary care”, explains Dr. Lars Wahlberg, CEO.